Occurrence of dMMR/MSI-H tumor during follow-up in Lynch syndrome patients treated with immune checkpoint inhibitors for metastatic digestive cancer

2015 and 2024: a retrospective analysis of a monocentric prospective cohort study

Highlights

Patients with LS treated with ICIs are at risk of metachronous dMMR/MSI-H cancers (8% of cohort).

The most frequent metachronous(occurring at different times) cancers observed were urothelial cancer and CRC.

Preneoplastic(state or lesion that occurs before the formation of a benign or malignant tumour) colorectal polyps developed in 39% of patients undergoing colonoscopies during follow-up.

Long-term surveillance is critical for LS patients post-ICI treatment.

https://www.esmoopen.com/article/S2059-7029(25)01428-0/fulltext